BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize

Rhea-AI Summary

BioArctic (NASDAQ Stockholm: BIOA B) announced that its founder, Professor Lars Lannfelt, will receive the prestigious 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering work in Alzheimer's disease research and the development of lecanemab.

Professor Lannfelt, who founded BioArctic in 2003 with Pär Gellerfors, made groundbreaking discoveries about the role of amyloid-beta protein in Alzheimer's disease. These findings led to the development of lecanemab, an antibody treatment that targets specific forms of amyloid-beta in the brain, developed in collaboration with Eisai. The treatment showed positive results in the global Phase 3 Clarity AD trial.

The award ceremony will take place in Bonn in November 2025. The prize, awarded biennially since 2011, recognizes outstanding research in neurodegenerative disorders.

STOCKHOLM, June 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering contributions to the understanding of Alzheimer's disease and to the development of the drug lecanemab. The prize is presented jointly by German Center for Neurodegenerative Diseases (DZNE) and the Piepenbrock Group. The award ceremony will take place in Bonn in November this year.

"I'm proud to have been awarded the 2025 Hartwig Piepenbrock-DZNE Prize. Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt. "It is inspiring to see how research in this field now has begun to take quantum leaps with the development of treatments such as lecanemab which demonstrated benefits to patients in the global Phase 3 Clarity AD trial using gold standard endpoints. Coupled with the introduction of modern diagnostic methods, I am convinced that we are facing a paradigm shift where, in time, we will be able to offer not just a slowdown in the progression of the disease but eventually be able to  halt the disease process."

Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease. These discoveries are the basis for lecanemab, an antibody treatment developed in collaboration with the Japanese company Eisai. By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear them from the brain, thereby altering the course of the disease.

Since 2011, the Hartwig Piepenbrock-DZNE Prize has been awarded every two years for outstanding research on neurodegenerative disorders. The prize is sponsored by the Piepenbrock Group and is awarded in remembrance of its former Chief Executive Officer and Chairman Hartwig Piepenbrock, who passed away after suffering from dementia. Prize winners are selected by an international committee, coordinated by DZNE. On this occasion, the prize will be awarded for the eighth time.

The information was released for public disclosure, through the agency of the contact persons below, on June 26, 2025, at 10.15 a.m. CET.

For further information, please contact: 
Oskar Bosson, VP Communications and IR
E-mail:  oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80 

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/professor-lars-lannfelt-to-receive-the-2025-hartwig-piepenbrock-dzne-prize,c4169136

The following files are available for download:

https://mb.cision.com/Main/9978/4169136/3526126.pdf

Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize

View original content:https://www.prnewswire.com/news-releases/bioarctic-professor-lars-lannfelt-to-receive-the-2025-hartwig-piepenbrock-dzne-prize-302492075.html

SOURCE BioArctic

FAQ

Who is Professor Lars Lannfelt and what did he win the 2025 Hartwig Piepenbrock-DZNE Prize for?

Professor Lars Lannfelt is the founder of BioArctic and won the prize for his pioneering contributions to understanding Alzheimer's disease and developing the drug lecanemab.

What is lecanemab and how does it work in treating Alzheimer's disease?

Lecanemab is an antibody treatment that works by binding to specific forms of amyloid-beta protein in the brain, helping to clear them and potentially altering the course of Alzheimer's disease.

When was BioArctic founded and by whom?

BioArctic was founded in 2003 by Professor Lars Lannfelt and Pär Gellerfors.

When and where will the Hartwig Piepenbrock-DZNE Prize ceremony take place?

The award ceremony will take place in Bonn, Germany in November 2025.